Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed using generative AI in heavily pretreated mesothelioma at ESMO 2026

By 26/10/2026No Comments1 Min Read

Previous ArticleInfineon Courts AI Start-ups and Tightens Power Supply Chain Ahead of November Results

Next Article Anthropic’s IPO: A close look at AI frontrunner’s rapid growth, spiraling costs